| Ridaforolimus studied in …STUDIED_INderived33 of 33show fewer |
|---|
| → studied in | NCT00694083Phase 1 · completed Study of Ridaforolimus (MK-8669) in Participants With Solid Tumors (MK-8669-003)(COMPLETED) · 33 trials list this drug (0 active) | — | — | Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00770185Phase 2 · completed Ridaforolimus in Treating Patients With Recurrent Metastatic and/or Locally Advanced Endometrial Cancer · 33 trials list this drug (0 active) | — | — | Malignant Endometrial Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01169532Phase 1 · completed Ridaforolimus and Vorinostat in Treating Patients With Advanced Solid Tumors or Lymphoma · 33 trials list this drug (0 active) | — | — | Adult Solid Neoplasm,Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01212627Phase 1 · terminated Ridaforolimus With Cetuximab: Adv Non-Small Cell Lung, Colorectal, Head & Neck Cancer · 33 trials list this drug (0 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00874731Phase 1 · completed A Study to Evaluate the Effect of MK-8669 (Ridaforolimus) on QTc Interval in Participants With Advanced Cancer (MK-8669-037) · 33 trials list this drug (0 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01380184Phase 1 · completed Pharmacokinetics of Ridaforolimus (MK-8669) in Chinese Participants (MK-8669-059) · 33 trials list this drug (0 active) | — | — | Malignant Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01605396Phase 2 · completed A Phase II Trial of Ridaforolimus and Exemestane, Compared to Ridaforolimus, Dalotuzumab and Exemestane in Participants With Breast Cancer (MK-8669-064) · 33 trials list this drug (0 active) | — | — | Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01431534Phase 1 · terminated A Study of Ridaforolimus in Pediatric Participants With Advanced Solid Tumors (MK-8669-056) · 33 trials list this drug (0 active) | — | — | Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00836927Phase 2 · terminated Extension Trial of Deforolimus (Ridaforolimus, MK-8669) in Participants With Advanced Cancer (MK-8669-038) · 33 trials list this drug (0 active) | — | — | Malignant Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01243762Phase 1 · terminated A Study of Dalotuzumab + MK-2206, Dalotuzumab + MK-0752, and Dalotuzumab + Ridaforolimus Combination Therapies in Participants With Advanced Cancer (MK-0646-027) · 33 trials list this drug (0 active) | — | — | Malignant Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01256268Phase 1 · completed Carboplatin/Taxol/Ridaforolimus in Endometrial, Ovarian and Solids · 33 trials list this drug (0 active) | — | — | Malignant Ovarian Neoplasm,Malignant Endometrial Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01234857Phase 2 · completed A Study of Ridaforolimus (MK-8669) in Combination With Dalotuzumab (MK-0646) Compared to Standard of Care Treatment in Estrogen Receptor Positive Breast Cancer Patients (MK-8669-041 AM3) · 33 trials list this drug (0 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01431547Phase 1 · completed Study of Dalotuzumab Alone and With Ridaforolimus in Pediatric Participants With Advanced Solid Tumors (MK-8669-062 AM1) · 33 trials list this drug (0 active) | — | — | Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00110188Phase 2 · completed Ridaforolimus (AP23573/MK-8669) in Participants With Taxane-Resistant Androgen-Independent Prostate Cancer (AIPC)(MK-8669-017) · 33 trials list this drug (0 active) | — | — | Malignant Prostate Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00060632Phase 1 · completed Safety Study of Ridaforolimus in Patients With Advanced, Refractory or Recurrent Malignancies (MK-8669-001 AM5)(COMPLETED) · 33 trials list this drug (0 active) | — | — | Neoplasm,Lymphoma,Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00060645Phase 1 · completed Safety Study of AP23573 in Patients With Advanced, Refractory or Recurrent Malignancies (8669-013)(COMPLETED) · 33 trials list this drug (0 active) | — | — | Neoplasm,Lymphoma,Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00736970Phase 2 · completed Oral Deforolimus With Trastuzumab for Patients With HER2-positive Trastuzumab-Refractory Metastatic Breast Cancer (8669-009) · 33 trials list this drug (0 active) | — | — | Breast Neoplasm,Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01295632Phase 1 · completed Safety and Tolerability of Different Dose Combinations of Ridaforolimus With MK-2206 or MK-0752 for Participants With Advanced Cancer (MK-8669-049) · 33 trials list this drug (0 active) | — | — | Malignant Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00086125Phase 2 · completed Study of AP23573 in Patients With Relapsed or Refractory Hematologic Malignancies (8669-024)(COMPLETED) · 33 trials list this drug (0 active) | — | — | Hematopoietic and Lymphoid Cell Neoplasm,Leukemia,Lymphoma+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00087451Phase 1 · completed Safety Study of AP23573 in Patients With Progressive or Recurrent Glioma (8669-023)(COMPLETED) · 33 trials list this drug (0 active) | — | — | Glioblastoma,Malignant Glioma,Gliosarcoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00777959Phase 2 · completed Bicalutamide and Ridaforolimus in Men With Prostate Cancer (MK-8669-002) · 33 trials list this drug (0 active) | — | — | Malignant Prostate Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00288431Phase 1 · completed Safety, Tolerability and Maximum Tolerated Dose of Oral AP23573 in Combination With Doxorubicin (8669-015) · 33 trials list this drug (0 active) | — | — | Malignant Neoplasm,Sarcoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00739830Phase 2 · completed Clinical Trial of Ridaforolimus Compared to Progestin or Chemotherapy for Advanced Endometrial Carcinoma (MK-8669-007 AM6) · 33 trials list this drug (0 active) | — | — | Malignant Endometrial Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01010672Phase 2 · completed Phase II Study of Ridaforolimus (MK-8669) With Metastatic Bone or Soft-tissue Sarcoma Patients (MK-8669-030 AM1) · 33 trials list this drug (0 active) | — | — | Sarcoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01071304Phase 1 · completed Effect of Ridaforolimus on the Pharmacokinetics of Midazolam (Study MK-8669-044) · 33 trials list this drug (0 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00122343Phase 2 · completed AP23573 in Female Adult Patients With Recurrent or Persistent Endometrial Cancer (8669-019)(COMPLETED) · 33 trials list this drug (0 active) | — | — | Malignant Endometrial Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00093080Phase 2 · completed Study of AP23573/MK-8669 (Ridaforolimus), A Mammalian Target of Rapamycin (mTOR) Inhibitor, in Participants With Advanced Sarcoma (MK-8669-018 AM1)(COMPLETED) · 33 trials list this drug (0 active) | — | — | Sarcoma,Liposarcoma,Osteosarcoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00538239Phase 3 · completed Ridaforolimus in Treatment of Sarcoma-SUCCEED (Sarcoma Multi-Center Clinical Evaluation of the Efficacy of Ridaforolimus)(8669-011 AM6) · 33 trials list this drug (0 active) | — | — | Bone Sarcoma,Soft Tissue Sarcoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00704054Phase 1 · completed A Multi-Center Phase I Study of Intravenous Deforolimus (AP23573, MK-8669) Administered QDX5 Every Other Week in Pediatric Patients With Advanced Solid Tumors (8669-028)(COMPLETED) · 33 trials list this drug (0 active) | — | — | Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00781846Phase 1 · completed Trial of Deforolimus in Combination With Bevacizumab for Patients With Advanced Cancers (8669-010)(COMPLETED) · 33 trials list this drug (0 active) | — | — | Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00112372Phase 1 · completed Study of Oral Ridaforolimus (AP23573, MK-8669) to Treat Patients With Refractory or Advanced Malignancies (MK-8669-016 AM4)(COMPLETED) · 33 trials list this drug (0 active) | — | — | Malignant Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01220570Phase 1 · completed The Growth Factor Signature (GFS) as an Intermediate Biomarker of Response for Development of PI3K-Pathway Inhibitors in Patients With Breast Cancer (MK-8669-050) · 33 trials list this drug (0 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01296659Phase 1 · withdrawn Study of Oral Ridaforolimus in Combination With Standard Chemotherapy for Soft Tissue Sarcoma · 33 trials list this drug (0 active) | — | — | Soft Tissue Sarcoma | 1 | Observed | clinicaltrials | graph → |